Marea Therapeutics, a San Francisco, CA-based clinical-stage biotechnology company incubated by Third Rock Ventures, raised $190M in combined Series A and B financings.
The Series A round was led by Third Rock Ventures and the Series B round was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund and venBio, with the participation of Alpha Wave Global, Omega Funds, Surveyor Capital (a Citadel company) and founding investor Third Rock Ventures.
The company intends to use the funds to advance its MAR001 Phase 2 development plan and additional pipeline programs.
Led by Josh Lehrer, M.D., M.Phil., FACC, chief executive officer, Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop medicines for cardiometabolic diseases. Its lead program, MAR001, is in Phase 2 clinical development to lower remnant cholesterol in adults with metabolic dysfunction and high risk for cardiovascular disease.
Marea founders include:
- Charles Homcy, M.D., partner emeritus, Third Rock Ventures
- Sir Stephen O’Rahilly, M.D., FRS, professor of clinical biochemistry and medicine, University of Cambridge
- Joshua Rabinowitz, M.D., Ph.D., professor of chemistry & integrative genomics, Princeton University
- Ethan J. Weiss, M.D., chief scientific officer
FinSMEs
19/06/2024